The WACC of Yew Bio-Pharm Group Inc (YEWB) is 5.7%.
| Range | Selected | |
| Cost of equity | 16.10% - 722.90% | 369.50% |
| Tax rate | 1.00% - 1.40% | 1.20% |
| Cost of debt | 5.10% - 5.60% | 5.35% |
| WACC | 5.0% - 6.4% | 5.7% |
| Category | Low | High |
| Long-term bond rate | 3.9% | 4.4% |
| Equity market risk premium | 4.6% | 5.6% |
| Adjusted beta | 2.66 | 128.23 |
| Additional risk adjustments | 0.0% | 0.5% |
| Cost of equity | 16.10% | 722.90% |
| Tax rate | 1.00% | 1.40% |
| Debt/Equity ratio | 868.46 | 868.46 |
| Cost of debt | 5.10% | 5.60% |
| After-tax WACC | 5.0% | 6.4% |
| Selected WACC | 5.7% | |
The Cost of Equity reflects the return a company needs to deliver to shareholders to justify the risk of investing in its shares. It’s computed using the Capital Asset Pricing Model (CAPM), which blends the risk-free rate, the stock’s beta, and the market risk premium.
This method evaluates the stock’s risk compared to a safe investment and the market’s overall volatility.
Here’s how we figure out the cost of equity for YEWB:
cost_of_equity (369.50%) = risk_free_rate (4.15%) + equity_risk_premium (5.10%) * adjusted_beta (2.66) + risk_adjustments (0.25%)
We include the risk adjustments, which range from 0% to 1%, to keep our WACC conservatives, especially for companies traded in developing markets.